Back to results
US 2008/0269281 A1Published application
Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs
OwnerThomas Trieselmann, Rainer Walter +2inventors
InventorsThomas Trieselmann, Rainer Walter, Matthew R. Netherton, Bradford S. Hamilton
Life of this patent
Estimating the term…
Abstract
Compounds of the formula which are selective beta-3-agonists and useful for the treatment of obesity and type II diabetes. Exemplary compounds are: ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylate and 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylic acid.
Claims10
1:
- A compound of the formula
- wherein
- R1 denotes a C1-4-alkyl, thienyl, pyridyl or phenyl group,
- wherein the phenyl group may be substituted by one to three fluorine, chlorine or bromine atoms or one to three C1-3-alkyl, C1-3-alkyloxy, trifluoromethoxy or difluoromethoxy groups, wherein the substituents may be identical or different,
- R2 denotes a benzimidazolyl group wherein a methyne group in the benzyl moiety is replaced by a nitrogen atom and
- which may additionally be substituted by a fluorine, chlorine or bromine atom, a cyano group or a C1-3-alkyl, carboxy, C1-4-alkyloxy-carbonyl or amino group,
- and R3 and R4, which may be identical or different, each represent a C1-3-alkyl group, while the alkyl groups contained in the above-mentioned groups may be straight-chain or branched,
- or a salt thereof.
5 more elements
2:
- A compound of the formula (I) according to claim 1, wherein
- R1 denotes a phenyl group,
- R2 denotes a benzimidazol-1-yl group wherein a methyne group in the benzyl moiety is replaced by a nitrogen atom and
- which is additionally substituted by a carboxy or C1-4-alkyloxy-carbonyl group,
- and R3 and R4 in each case represent a methyl group,
- or a tautomer or salt thereof.
3 more elements
3:
- A compound according to claim 1 wherein the compound is the (R)-enantiomer of formula
4:
- A compound according to claim 1 wherein the compound is the (S)-enantiomer of formula
5:
- A compound according to claim 1 selected from the group consisting of:
- ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylate;
- 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-b]pyridine-5-carboxylic acid;
- ethyl 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-c]pyridine-6-carboxylate;
- 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid;
- ethyl 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-b]pyridine-5-carboxylate;
- 1-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-imidazo[4,5-b]pyridine-5-carboxylic acid;
- ethyl 3-{3-[(R)-2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-c]pyridine-6-carboxylate;
- and
- 3-{3-[2-(3-benzenesulphonylamino-phenyl)-2-hydroxy-ethylamino]-3-methyl-butyl}-3H-imidazo[4,5-c]pyridine-6-carboxylic acid;
- or an enantiomer or salt thereof.
8 more elements
6:
- A physiologically acceptable salt of a compound according to claim 1, 2, 3, 4 or 5.
7-10. (canceled)
11:
- A pharmaceutical composition comprising a compound according to claim 1, 2, 3, 4 or 5 or a pharmaceutically acceptable salt thereof and a carrier or excipient.
12-13. (canceled)
14:
- A method for the treatment of obesity or type II diabetes which comprises administering to a host suffering from the same a therapeutically effect amount of a compound according to claim 1, 2, 3, 4 or 5 or a pharmaceutically acceptable salt thereof.